Personalized follow-up of circulating DNA in resected stage III/IV melanoma: PERCIMEL multicentric prospective study protocol

BACKGROUND: With more than 15,000 new cases /year in France and 2,000 deaths, cutaneous melanoma represents approximately 4% of incidental cancers and 1.2% of cancer related deaths. In locally advanced (stage III) or resectable metastatic (stage IV) melanomas, medical adjuvant treatment is proposed...

Descripción completa

Detalles Bibliográficos
Autores principales: Geoffrois, Lionnel, Harlé, Alexandre, Sahki, Nassim, Sikanja, Aleksandra, Granel-Brocard, Florence, Hervieu, Alice, Mortier, Laurent, Jeudy, Géraldine, Michel, Catherine, Nardin, Charlée, Huin-Schohn, Cécile, Merlin, Jean-Louis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10273694/
https://www.ncbi.nlm.nih.gov/pubmed/37328818
http://dx.doi.org/10.1186/s12885-023-11029-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10273694/
https://www.ncbi.nlm.nih.gov/pubmed/37328818
http://dx.doi.org/10.1186/s12885-023-11029-4

Ejemplares similares